'Disease progression' presentation slideshows

MS Patient Cases Iran May 2007

MS Patient Cases Iran May 2007. Jack Burks, MD Clinical Professor, Neurologist University of Nevada School of Medicine Reno, Nevada Vice President/Chief Medical Officer Multiple Sclerosis Association of America President Multiple Sclerosis Alliance.

1.7k views • 124 slides

Hepatitis and HIV

Hepatitis and HIV Catherine Creticos, M.D. August, 2007 Case study 1

1.56k views • 100 slides

Human Immunodeficiency Virus: An Overview

Human Immunodeficiency Virus: An Overview. Elizabeth W. Delamater, Ph.D. Manager, Microbiological Sciences Division Laboratory Services Section Texas Department of State Health Services. HIV-1. HTLV-I. HIV-2. HTLV-II. (SIV). (STLV-I). Common Ancestor. Transforming Viruses

962 views • 71 slides

IMMUNOTHERAPY IN ALLERGIC DISEASES

IMMUNOTHERAPY IN ALLERGIC DISEASES. Dr Narayan Pradeep Pulmonologist kasaragod. IMMUNOTHERAPY IN ALLERGIC DISEASES. History Definition Is it useful? Is it harmful? Mechanisms of action Indications Contraindications. IMMUNOTHERAPY IN ALLERGIC DISEASES. Guidelines for immunotherapy

1.59k views • 64 slides

Atrasentan For Men with Metastatic Hormone Refractory Prostate Cancer ODAC September 13 th , 2005

Atrasentan For Men with Metastatic Hormone Refractory Prostate Cancer ODAC September 13 th , 2005. Clinical-Statistical Presentation Amna Ibrahim MD Shenghui Tang PhD DDOP, FDA. Outline of Presentation. 1- Past approvals 2- Phase III study Study design

791 views • 56 slides

DIFFERENTIATING MOVEMENT DISORDERS

DIFFERENTIATING MOVEMENT DISORDERS. B. WAYNE BLOUNT, MD, MPH PROFESSOR, EMORY S.O.M. QUESTION # 1. WHICH OF THE BELOW ARE FEATURES TO USE IN DIFFERENTIATING MOVEMENT DISORDERS? A. WHETHER OR NOT THE MOVEMENTS ARE HYPOKINETIC VS. HYPERKINETIC B. PRESENCE OF A TREMOR C. TYPE GAIT

1.85k views • 52 slides

Post Myocardial Infarction

Post Myocardial Infarction. Pharmacotherapy. ASA & Anti-platelet agents Anti-coagulation ?- blockers ACE inhibitors Dyslipidemic therapy Statins Fibrates. Post MI Pharmacologic Intervention. ASA & Anti-platelet agents. Rationale: Ruptured plaque platelet activation & aggregation

768 views • 49 slides

Impact and management strategies for Phellinus noxius in the urban environment

Impact and management strategies for Phellinus noxius in the urban environment. Michelle Grose Agri-science Queensland. Presentation Outline. What is Phellinus noxius ? Disease significance Phellinus project Symptom development Aetiology of Phellinus in the urban environment

963 views • 41 slides

Learning Objectives

Learning Objectives. After completing this activity, participants should be able to: Outline patient signs and symptoms that should lead to an evaluation for NETs Describe the diagnostic work-up that can confirm a suspected diagnosis of NET

1.09k views • 39 slides

State of the Art

544 views • 33 slides

AGING AND THE PERIODONTIUM

AGING AND THE PERIODONTIUM. CONTENTS. Introduction Definition Classification General effects of aging The aging periodontium Periodontal disease in older adults Effects of aging on periodontal disease progression Periodontal treatment planning Response to treatment of the periodontium

2.76k views • 32 slides

Multiple Sclerosis

Multiple Sclerosis. Walter Royal, III, MD Associate Professor, Department of Neurology University of Maryland School of Medicine Director, Maryland Center for Multiple Sclerosis Treatment and Research. What is Multiple Sclerosis?.

1.74k views • 30 slides

617 views • 29 slides

Howard I. Scher, MD Chief, Genitourinary Oncology Service Memorial Sloan Kettering Cancer Center October 6, 2009

Advanced Stage Disease: Management of Disease Progression and Emerging Drug Protocols. Howard I. Scher, MD Chief, Genitourinary Oncology Service Memorial Sloan Kettering Cancer Center October 6, 2009. Advanced Stage Disease. Clinical States: A framework for drug development.

462 views • 27 slides

Cultural and Genetic Diversity in America: The Need for Individualized Pharmaceutical Care

344 views • 19 slides

44th Annual Meeting of the European Association for the Study of the Liver Friday, April 24, 2009 Copenhagen, Denmark

J Bruix, T Poynard, M Colombo, E Schiff, J Reichen, K Burak, EJL Heathcote, T Berg, J-L Poo, C Brandao Mello, R Guenther, C Niederau, R Terg, N Boparai, J Harvey, LH Griffel, M Burroughs, CA Brass, JK Albrecht for the EPIC 3 Study Group.

418 views • 18 slides

Pulmonary Rehabilitation In COPD

Pulmonary Rehabilitation In COPD. Dr. Alastair Jackson September 2004. What is Pulmonary Rehabilitation?.

953 views • 14 slides

CMD Clinical Trial Readiness Campaign

CMD Clinical Trial Readiness Campaign. The CMD genes ~ The CMD to LGMD spectrum. Congenital Myopathy- RYR1. There is an overlap between congenital muscular dystrophy and congenital myopathy .

305 views • 13 slides

Should Genetic Risk for ARMD Play a Role in Intra-Ocular Lens Selection?

Should Genetic Risk for ARMD Play a Role in Intra-Ocular Lens Selection? . Steve A. Arshinoff MD FRCSC Humber River Regional Hospital Departments of Ophthalmology and Vision Sciences, University of Toronto & McMaster University. UV 400 filtering ?. Blue Light Filtering ?. Multifocal ?.

412 views • 12 slides

Glucosamine

315 views • 9 slides